Johnson & Johnson (JNJ)

Long-term investors should skip the SpaceX roller coaster, and pivot toward these three Dividend Kings instead.

Get rich slowly. How? Hold these stocks and reinvest the dividends they pay.

Young adults with median earnings can build sizable portfolios that pay a hefty amount of passive income by retirement.

These well-established companies are on track to deliver more growth.

In an unstable market, these three companies offer investors a chance to own durable consumer businesses that generate steady growth regardless of economic headlines.

Bear markets are a part of investing life, but you can prepare for them ahead of time.

Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound.

It could be a great move by the billionaire hedge fund manager.

Medical science's capabilities are catching up with what it knows about the genomics of disease. J&J just made sure it's better equipped to utilize the industry's newest capabilities.

New cancer therapies may help fund dividend growth.

It's important to consider your comfort with risk before diving in.

Johnson & Johnson reports Phase 2/3 data showing IMAAVY improved hemoglobin levels in wAIHA patients and secured FDA Priority Review.